I see Rengeneron is suing Sandoz over a bio similar to Eylea. Since the advent of generic competition Eylea sales have dipped 9% to $5.7B USD. The market is ripe for a combination therapy which significantly improves visual acuity and can be used with Eylea, Lucentis or bio similars. Surely Regeneron sees Sozinibercept as an opportunity to bolster faltering sales? Opthea is primed for a takeover and I reckon it will happen very quickly if the results are good in April. A purchase price equal to Eylea annual sales doesn't seem unreasonable.
I see Rengeneron is suing Sandoz over a bio similar to Eylea....
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
85.0¢ |
Change
0.025(3.03%) |
Mkt cap ! $1.046B | |||
| Open | High | Low | Value | Volume |
| 82.0¢ | 87.0¢ | 81.0¢ | $2.966M | 3.483M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 84.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 85.0¢ | 980 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |